Literature DB >> 10401935

Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome.

F Strutz1, G Heller, K Krasemann, B Krone, G A Müller.   

Abstract

OBJECTIVES: To assess the prognostic value of determining anti-endotoxin core antibodies (EndoCab) immunoglobulin (Ig)G and IgM in medical patients with sepsis syndrome in order to identify patient subgroups that may profit from endotoxin-neutralizing therapy. The findings were correlated with clinical outcome, endotoxin levels and sepsis score.
DESIGN: Cohort study with a follow-up period of 30 days.
SETTING: Medical intensive care units (2) of a university hospital. PATIENTS AND METHODS: Twenty-nine patients who fulfilled the criteria of sepsis syndrome and did not present with septic shock or had not been treated with antibiotics for more than 3 days were included in the study. Twenty-one intensive care patients without infections served as controls for antibody concentrations.
INTERVENTIONS: Blood samples were obtained from indwelling arterial catheters or direct venipuncture on admission and daily thereafter until transfer to a regular unit. Sepsis scores were determined daily.
RESULTS: The mortality rate at 30 days was 44.8% (13 out of 29). Sepsis patients had significantly lower initial EndoCab IgM and IgG concentrations than controls. Initial EndoCab IgG concentrations were significantly lower in non-survivors of sepsis syndrome but not in survivors compared to controls (median concentrations 51.5 vs 110.1 vs 245.4 MU/ml). EndoCab IgM and IgG were lower in non-survivors compared to survivors, though that difference failed to reach significance (p = 0.11 in both cases). Depletion of initial EndoCab IgM concentrations (defined as a value below the 10th percentile of a control population) was present in 15 patients, 9 of whom died, and depletion of IgG in five patients, four of whom died. EndoCab IgM and IgG concentrations rose concordantly in survivors and non-survivors in the course of the disease. Endotoxin levels were significantly higher in non-survivors compared to controls but not in survivors. A sepsis score of 21 and higher was associated with 90.9% mortality (specificity 93.8%, sensitivity 76.9%).
CONCLUSIONS: Decreased EndoCab IgG concentrations are associated with increased mortality in medical patients with sepsis syndrome. The measurement of initial anti-endotoxin antibodies may provide a useful tool to identify septic patients who profit potentially from endotoxin neutralizing therapy, however considerable overlap of antibody concentrations warrants additional parameters. The sepsis score is easy to determine and useful in the evaluation of medical patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401935     DOI: 10.1007/s001340050877

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

1.  Non-invasive assessment of barrier integrity and function of the human gut.

Authors:  Joep Grootjans; Geertje Thuijls; Froukje Verdam; Joep Pm Derikx; Kaatje Lenaerts; Wim A Buurman
Journal:  World J Gastrointest Surg       Date:  2010-03-27

2.  Endotoxemia as a diagnostic tool for patients with suspected bacteremia caused by gram-negative organisms: a meta-analysis of 4 decades of studies.

Authors:  James C Hurley; Piotr Nowak; Lars Öhrmalm; Charalambos Gogos; Apostolos Armaganidis; Evangelos J Giamarellos-Bourboulis
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

3.  Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Andrea Foulkes; Avy Violari; Mark F Cotton; Maxwell Pistilli; Griffin Reynolds; Xiangfan Yin; Deborah K Glencross; Wendy S Stevens; James A McIntyre; Luis J Montaner
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

Review 4.  Environmental enteropathy: critical implications of a poorly understood condition.

Authors:  Poonum S Korpe; William A Petri
Journal:  Trends Mol Med       Date:  2012-05-25       Impact factor: 11.951

5.  Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children.

Authors:  R C M Stephens; K Fidler; P Wilson; G R Barclay; M G Mythen; G L J Dixon; M W Turner; N J Klein; M J Peters
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

Review 6.  Microbial translocation across the GI tract.

Authors:  Jason M Brenchley; Daniel C Douek
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

7.  Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Authors:  Emmanouil Papasavvas; Maxwell Pistilli; Griffin Reynolds; Robert Bucki; Livio Azzoni; Jihed Chehimi; Paul A Janmey; Mark J DiNubile; Joe Ondercin; Jay R Kostman; Karam C Mounzer; Luis J Montaner
Journal:  AIDS       Date:  2009-01-28       Impact factor: 4.177

Review 8.  Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confounders.

Authors:  James C Hurley; Bertrand Guidet; Georges Offenstadt; Eric Maury
Journal:  Crit Care       Date:  2012-08-07       Impact factor: 9.097

Review 9.  Intestinal permeability--a new target for disease prevention and therapy.

Authors:  Stephan C Bischoff; Giovanni Barbara; Wim Buurman; Theo Ockhuizen; Jörg-Dieter Schulzke; Matteo Serino; Herbert Tilg; Alastair Watson; Jerry M Wells
Journal:  BMC Gastroenterol       Date:  2014-11-18       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.